ARCHIVES

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

This article is from The Cancer Letter archive.

Vol. 23 No. 37 | September 26, 1997

Download PDF Visit The Full Archive

Related Articles

Faulty Estimates Led NCI To Overstate Black-White Cancer Disparity In Atlanta

September 20, 2002

Sequestration Hurts Kids with Cancer

March 15, 2013

As Zeneca Buys Salick, Implications For Oncology Managed Care Uncertain

April 4, 1997

FDA Advisors Oppose Group’s Tamoxifen Trial, But Okay The Idea

July 6, 1990

Cost of Care: Medicare Patients Charged More In Outpatient Care Settings

November 1, 2013

FDA Lacks Resources To Deal With Onslaught Of New Cancer Drugs, Friedman Tells Agency

August 14, 1992